与年龄相关的听力损失的基因组学和药物基因组学

Q4 Pharmacology, Toxicology and Pharmaceutics Current Pharmacogenomics and Personalized Medicine Pub Date : 2021-08-23 DOI:10.2174/1875692118666210823115347

J. Guerra, V. Naidoo, R. Cacabelos

{"title":"与年龄相关的听力损失的基因组学和药物基因组学","authors":"J. Guerra, V. Naidoo, R. Cacabelos","doi":"10.2174/1875692118666210823115347","DOIUrl":null,"url":null,"abstract":"\n\nAge-related hearing loss (ARHL) or presbycusis shares common features with conditions related to senescence and neurodegeneration. In this review, we explore the linking of genes involved in such processes with presbycusis, that has been proven to share important relationships with genes involved in dementia (APOE and MTHFR), ototoxicity (the GST group), and pharmacogenetics (NAT2). In this regard, we propose the construction of pharmacogenetics for the presbycusis database that could help better control side effects in this particularly vulnerable population susceptible to neurodegenerative disorders. Moreover, preliminary epigenetics studies have recently identified links in human genes involved in ARHL, which could serve as biomarkers or as therapeutic targets. \n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Genomics and Pharmacogenomics of Age-Related Hearing Loss\",\"authors\":\"J. Guerra, V. Naidoo, R. Cacabelos\",\"doi\":\"10.2174/1875692118666210823115347\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nAge-related hearing loss (ARHL) or presbycusis shares common features with conditions related to senescence and neurodegeneration. In this review, we explore the linking of genes involved in such processes with presbycusis, that has been proven to share important relationships with genes involved in dementia (APOE and MTHFR), ototoxicity (the GST group), and pharmacogenetics (NAT2). In this regard, we propose the construction of pharmacogenetics for the presbycusis database that could help better control side effects in this particularly vulnerable population susceptible to neurodegenerative disorders. Moreover, preliminary epigenetics studies have recently identified links in human genes involved in ARHL, which could serve as biomarkers or as therapeutic targets. \\n\",\"PeriodicalId\":11056,\"journal\":{\"name\":\"Current Pharmacogenomics and Personalized Medicine\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-08-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Pharmacogenomics and Personalized Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1875692118666210823115347\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692118666210823115347","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 1

摘要

年龄相关性听力损失(ARHL)或老年性耳聋与衰老和神经退行性疾病有共同的特征。在这篇综述中，我们探讨了参与这些过程的基因与老年性耳聋的联系，这些基因已被证明与痴呆(APOE和MTHFR)、耳毒性(GST组)和药物遗传学(NAT2)相关的基因具有重要关系。在这方面，我们建议为老年性痴呆数据库构建药物遗传学，以帮助更好地控制这一特别易患神经退行性疾病的易感人群的副作用。此外，初步的表观遗传学研究最近已经确定了与ARHL有关的人类基因的联系，这些联系可以作为生物标志物或治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Genomics and Pharmacogenomics of Age-Related Hearing Loss

Age-related hearing loss (ARHL) or presbycusis shares common features with conditions related to senescence and neurodegeneration. In this review, we explore the linking of genes involved in such processes with presbycusis, that has been proven to share important relationships with genes involved in dementia (APOE and MTHFR), ototoxicity (the GST group), and pharmacogenetics (NAT2). In this regard, we propose the construction of pharmacogenetics for the presbycusis database that could help better control side effects in this particularly vulnerable population susceptible to neurodegenerative disorders. Moreover, preliminary epigenetics studies have recently identified links in human genes involved in ARHL, which could serve as biomarkers or as therapeutic targets.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Pharmacogenomics and Personalized Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.